Fusion Antibodies PLC (FAB) — Capital Reinvestment Ratio
Fusion Antibodies PLC (FAB) has a Capital Reinvestment Ratio of 0.39x as of March 2022, meaning it reinvests 0% of its operating cash flow (GBX174.00K) in capital expenditures (GBX67.00K). Check tangible equity quality of Fusion Antibodies PLC to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Fusion Antibodies PLC Capital Reinvestment Ratio (2016–2018)
This chart tracks Fusion Antibodies PLC's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see FAB operating cash flow.
Annual Capital Reinvestment Ratio for Fusion Antibodies PLC (2016–2018)
Year-by-year Capital Reinvestment Ratio for Fusion Antibodies PLC from 2016 to 2018. See Fusion Antibodies PLC free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 5.76x | GBX77.19K | GBX444.60K | ▲ +5481.8% |
| 2016 | 0.10x | GBX346.57K | GBX35.76K | — |